MHRA Approves Phase I/II Clinical Trial of IN3BIO Vaccine to Improve Outcomes for Colorectal Cancer PatientsNews / By In3Bio March 9, 2022 - IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant promise and appear to be more tolerable for patients, announces today that it has received Clinical Trial Application approval from the British Medicines & Healthcare Products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial of its colorectal cancer vaccine. This is the company's second global regulatory approval for the trial, having obtained approval to conduct the study in Bulgaria earlier this year. With these approvals, IN3BIO is one step closer to bringing its innovative cancer treatments to market. The company is in the process of a Series A financing round for the Phase I/II trial as well as for developing a second molecule to advance its global mission.Link: https://www.globenewswire.com/news-release/2022/03/09/2400128/0/en/MHRA-Approves-Phase-I-II-Clinical-Trial-of-IN3BIO-Vaccine-to-Improve-Outcomes-for-Colorectal-Cancer-Patients.html
